218 related articles for article (PubMed ID: 15738379)
21. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
22. A practical update on the use of bortezomib in the management of multiple myeloma.
San Miguel J; Bladé J; Boccadoro M; Cavenagh J; Glasmacher A; Jagannath S; Lonial S; Orlowski RZ; Sonneveld P; Ludwig H
Oncologist; 2006 Jan; 11(1):51-61. PubMed ID: 16401713
[TBL] [Abstract][Full Text] [Related]
23. [Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
Sanada Y; Nakazato T; Suzuki K; Mihara A; Aisa Y; Iwabuchi M; Kakimoto T
Rinsho Ketsueki; 2010 Apr; 51(4):264-9. PubMed ID: 20467223
[TBL] [Abstract][Full Text] [Related]
24. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Wu KL; Heule F; Lam K; Sonneveld P
J Am Acad Dermatol; 2006 Nov; 55(5):897-900. PubMed ID: 17052502
[TBL] [Abstract][Full Text] [Related]
25. [Bortezomib-induced acute neutrophilic dermatosis].
Tanguy-Schmidt A; Avenel-Audran M; Croué A; Lissandre S; Dib M; Zidane-Marinnes M; Moles MP; Hunault-Berger M
Ann Dermatol Venereol; 2009 May; 136(5):443-6. PubMed ID: 19442803
[TBL] [Abstract][Full Text] [Related]
26. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695
[TBL] [Abstract][Full Text] [Related]
27. Complete heart block secondary to bortezomib use in multiple myeloma.
Dasanu CA
J Oncol Pharm Pract; 2011 Sep; 17(3):282-4. PubMed ID: 20406745
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib for myeloma -- much ado about something.
Dispenzieri A
N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
[No Abstract] [Full Text] [Related]
29. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.
Miyakoshi S; Kami M; Yuji K; Matsumura T; Takatoku M; Sasaki M; Narimatsu H; Fujii T; Kawabata M; Taniguchi S; Ozawa K; Oshimi K
Blood; 2006 May; 107(9):3492-4. PubMed ID: 16410442
[TBL] [Abstract][Full Text] [Related]
30. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
31. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
[TBL] [Abstract][Full Text] [Related]
32. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Tong Y; Qian J; Li Y; Meng H; Jin J
Am J Hematol; 2007 May; 82(5):403-4. PubMed ID: 17133426
[TBL] [Abstract][Full Text] [Related]
33. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
Kenealy MK; Prince HM; Hönemann D
Pharmacotherapy; 2006 Aug; 26(8):1205-6; discussion 1206. PubMed ID: 16863501
[No Abstract] [Full Text] [Related]
34. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
[TBL] [Abstract][Full Text] [Related]
36. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
37. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
[TBL] [Abstract][Full Text] [Related]
38. Immune-mediated neuropathies in myeloma patients treated with bortezomib.
Ravaglia S; Corso A; Piccolo G; Lozza A; Alfonsi E; Mangiacavalli S; Varettoni M; Zappasodi P; Moglia A; Lazzarino M; Costa A
Clin Neurophysiol; 2008 Nov; 119(11):2507-12. PubMed ID: 18829381
[TBL] [Abstract][Full Text] [Related]
39. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]